Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3001593 | 0.94 | L3MBTL1 (0.41) | CNR1PLA2G4AEPHX2FAAHMAPT | |
| SCHEMBL3002042 | 0.94 | PLA2G4A (0.43) | PLA2G4AEPHX2MAPTLMNAALDH1A1 | |
| SCHEMBL3005953 | 0.93 | FAAH (0.48) | CNR1PLA2G4AEPHX2FAAHMAPT | |
| SCHEMBL3008471 | 0.92 | TYK2 (0.42) | PLA2G4AEPHX2FAAHMAPTLMNA | |
| SCHEMBL3001761 | 0.92 | LMNA (0.46) | CNR1EPHX2MAPTLMNAALDH1A1 | |
| SCHEMBL2996462 | 0.92 | KCNH2 (0.45) | PLA2G4AFAAHMAPTSMN1; SMN2USP2 | |
| SCHEMBL3006717 | 0.91 | THRB (0.42) | PLA2G4AEPHX2FAAHMAPTLMNA | |
| SCHEMBL3008225 | 0.91 | PLA2G2A (0.45) | FAAHMAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL3007524 | 0.90 | FAAH (0.48) | PLA2G4AFAAHMAPTALOX12MEN1 | |
| SCHEMBL3010861 | 0.90 | MEN1 (0.44) | FAAHMAPTLMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118503-A1 | FAAH INHIBITORS | FAAH, FAAH2, CNR2 | CNR1 6/4885PLA2G4A 86/4885EPHX2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.